http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Young Jae Byun ),( Kyo Sang Yoo ),( Dong Soo Han ),( Joo Hyun Sohn ),( Yong Cheol Jeon ),( Chang Soo Eun ),( Tae Yeop Kim ),( Sun Min Kim ),( Youngouk Ro ),( Ji Yeon Kim ),( Jong Kwan Jeong ) 대한내과학회 2014 대한내과학회 추계학술발표논문집 Vol.2014 No.1
Background: The propofol sedation method for deep sedation during ERCP is not established yet. Because of very short duration of propofol action, it is frequently more difficult to maintain constant level of sedation, required for ERCP, by intermittent bolus injection compared to continuous infusion. This fluctuation of sedation level sometimes makes it diffi cult to perform complex ERCP. This study was conducted to compare sedation effi ciency, safety and satisfaction between continuous infusion and intermittent bolus injection of propofol for deep sedation during ERCP. Methods: 222 patients were randomly assigned to either continuous infusion or midazolam plus intermittent bolus injection of propofol. Continuous group: Propofol was continuously administered via infusion pump and the doses were determined by sedation assistants. Intermittent group: A loading dose of 2 mg of midazolam and 0.4 mg/Kg of propofol was initially injected and repeated bolus injection of 20 mg was followed according to sedation level. Sedation related parameters and adverse events during ERCP were evaluated. Satisfaction scores and diffi culty scores of maintaining the sedation were also graded after ERCP. Results: Induction time was similar between two groups, but recovery time was longer in the intermittent group. Satisfaction score was higher in the continuous group. Additionally, diffi culty score of maintaining the sedation was lower in the continuous group. Larger amounts of propofol was used in the continuous group. Adverse events of transient hypoxemia occurred in eight patients and were recovered by chin lifting or ambu bagging. However the adverse events were not signifi cantly different between two groups. Conclusions: Continuous infusion of propofol was more effi cient to maintain the constant level of sedation and more comfortable to endoscopist and sedation assistants for deep sedation during ERCP without increasing the risk of adverse events of deep sedation.
( Sang Jun Suh ),( Hyung Joon Yim ),( Young-sun Lee ),( Han Ah Lee ),( Tae Hyung Kim ),( Sun Young Yim ),( Young Kul Jung ),( Ji Hoon Kim ),( Yeon Seok Seo ),( Jong Eun Yeon ),( Kwan Soo Byun ),( Soon 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: Various models for the prediction of hepatocellular carcinoma (HCC) in the patients with chronic hepatitis B (CHB) were suggested. The aim of study is to identify if the HCC risk scores are improved as antiviral therapy is prolonged in the patients with CHB-related liver cirrhosis. Methods: The patients with CHB who received entecavir (ETV) or tenofovir (TDF) were investigated retrospectively. Patients with liver cirrhosis patients diagnosed by sonography, CT or biopsy were enrolled. We calculated the HCC risk scores at pre-antiviral therapy, and each year from year 1 to 5 of post-antiviral therapy. The models were GAG-HCC, CU-HCC, REACH-B, modified REACH-B (mREACH-B), LSM-HCC, and PAGE-B. The primary endpoint was decrease of the risk scores after antiviral therapy. The secondary endpoint was finding the best model by AUROC after antiviral therapy. Results: A total of 362 patients were enrolled, and 198 and 164 patients were treated by ETV and TDF respectively. Child- Pugh scores were 5.7±1.3 and MELD were 9.9±3.8. Fifty six patient (15.5 %) occurred HCC at median 1.6 years (0.1-9.7 years). Most HCC scores (GAG, CU-HCC, REACH-B) decreased at year 1 and plateaued from year 1 to 5. mREACH-B and LSM-HCC scores decreased until year 2 and plateaued after year 2. PAGE-B showed no decrease from pre to post-antiviral therapy. The AUROC of PAGE-B was largest at baseline (GAG-HCC 0.472, CU-HCC 0.753, REACH-B 0.633, mREACH-B 0.688, LSM-HCC 0.649, and PAGE-B 0.760). After antiviral therapy, the AUROC changed. AUROCs of models employing HBV DNA levels increased (GAG-HCC, REACH-B, and LSM-HCC), that of liver stiffness based models (mREACH-B and PAGE-B) were persistent, and that of models employing hepatic function (CU-HCC) decreased (GAG-HCC 0.582, CU-HCC 0.686, REACH-B 0.689, mREACH-B 0.689, LSM-HCC 0.716, and PAGE-B 0.755 at 1year). The decrease of scores from baseline to each years were not different between ETV and TDF (all P>0.05). AUROC were largest in PAGE-B, however the scores were not changed after antiviral therapy. Second largest AUROC is that of LSM-HCC at year 1 and its AUROC became larger after antiviral therapy Conclusions: In conclusion, HCC prediction models such as PAGE-B and LSM-based models worked well in patients with HBV-related cirrhosis and decrease of the scores was associated with effects of the antiviral therapy.
Exosome Derived from Palmitic Acid-treated Hepatocytes Activates Hepatic Stellate Cells
( Young-sun Lee ),( Eunjung Ko ),( Yang Jae Yoo ),( Jihye Je ),( Sang Jun Suh ),( Young Kul Jung ),( Ji Hoon Kim ),( Yeon Seok Seo ),( Hyung Joon Yim ),( Jong Eun Yeon ),( Kwan Soo Byun ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Although nonalcoholic fatty liver disease (NAFLD) is becoming dominant cause of chronic liver disease, the exact mechanism of progression from simple steatosis to nonalcoholic steatohepatitis (NASH) have yet to be elucidated. We aimed to investigate the role of exosome from lipid laden hepatocyte in the context of NAFLD progression in vitro. Methods: We isolated exosome from human hepatoma cell lines (Huh7 or HepG2) treated with palmitic acid (PA). Concentration of exosome was determined with exosome quantitation assay kit. LX-2 cells, human hepatic stellate cell (HSC) line, were treated with isolated exosome from PA treated cells. Fibrosis marker including transforming growth factor beta1 (TGF-b1), alpha-smooth muscle actin (a-SMA) and collagen type 1 alpha 1 (Col1a1) expression were measured. Results: Compare with controls, PA-treated hepatocytes significantly increased CD36 and exosome production (8.6 vs. 5.5 X 10^7 /μL, p <0.01). When LX-2 cells were cultured with exosome from hepatocytes, TGF-β1, α-SMA, and Col1a1 expression in LX-2 cells were significantly increased compared to control. Moreover, exosome from PA-treated hepatocytes more increased the expression levels of fibrosis markers. High concentration of exosome (100 μg/mL) more increased the expression levels of fibrosis markers compared to low concentration of exosome (50 μg/mL). Conclusions: Palmitic acid treatment enhanced the production of exosome in hepatocytes. Exosomes derived from palmitic acid-treated hepatocytes increased expression levels of fibrotic genes in HSCs. Therefore, exosome might have important roles for crosstalk between hepatocytes and HSCs in the progression to NASH from simple steatosis.
( Sang Young Byun ),( Bo Ri Kim ),( Jae Woo Choi ),( Sang Woong Youn ) 대한피부과학회 2016 Annals of Dermatology Vol.28 No.1
Because nail psoriasis is difficult to treat, therapy with many biological drugs has been attempted. Ustekinumab is approved for chronic plaque psoriasis and psoriatic arthritis (PsA), with some trials reporting nail improvement using this agent. A 51-year-old man with severe chronic plaque psoriasis had severe involvement of all fingernails and toenails, with accompanying nail fold psoriasis. He also had PsA of the small joints of the fingers. Despite multiple conventional therapies, the nail lesions did not improve, and his nail psoriasis severity index score was 97. After a fourth ustekinumab injection, most of the fingernail psoriasis was resolved, and only hyperkeratosis remained on both large toenails. Because the nail plate, nail fold, and small joints of the fingers are closely apposed structures within a small area, cytokines produced from the nail units overflow to the nail fold and small joints and can induce nail fold psoriasis and PsA.
( Young-Suk Lim ),( Hyung Joon Kim ),( Ki Tae Yoon ),( Won Young Tak ),( Jae-Seok Hwang ),( Sang Hoon Ahn ),( Kwan Soo Byun ),( Seung Woon Paik ),( Sook-Hyang Jeong ),( Yoon Jun Kim ),( So Young Kwon 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: TAF has shown similar efficacy to TDF with less bone and renal effects in 2 large multinational Phase 3 studies after 96weeks(2 years) of double-blind (DB) treatment. Here we evaluated efficacy and safety, including bone and renal parameters, in the subset of patients from East Asia(EA) who completed 2years of DB treatment with TAF 25mg or TDF 300mg once daily and were switched to open label(OL) TAF 25mg once daily for 1year. Methods: In 2 identically-designed studies, 1298 CHB patients who were HBeAgnegative (Study 108; N=425) or HBeAgpositive(Study 110; N=873) were randomized and treated. At Week96, 540(42%; TAF 360; TDF 180) patients including 240(18%; TAF 156; TDF 84) EA patients, had completed 2years of DB TAF or TDF treatment and been switched to OL TAF. Safety including bone(serial DXA scans of spine and hip) and renal(CrCl by Cockcroft-Gault [eGFR<sub>CG</sub>]) parameters, viral suppression and biochemical response were assessed at Year 3. Results: In EA patients on DB TDF switched to OL TAF(TDF<sup>®</sup>TAF), eGFRCG improved at Year 3 vs. Year 2 (median [Q1, Q3] change = +3.0 [-3.0, +8.4] ml/min); and was stable in those continuing TAF(TAF<sup>®</sup>TAF)(figure). BMD also improved at Year 3 vs. Year 2 in TDF<sup>®</sup>TAF patients (mean[SD]% change: spine = +2.2%[3.48]; hiP=+0.7%[2.44]) while BMD changes were stable for TAF<sup>®</sup>TAF patients (figure). High rates of virologic control (HBV DNA<29IU/mL) were maintained in those on treatment at Year3 vs Year2(TDF<sup>®</sup>TAF 96% and 95% and TAF<sup>®</sup>TAF 90% and 93%); ALT normalization (AASLD criteria) increased in TDF<sup>®</sup>TAF patients and was similar to TAF<sup>®</sup>TAF patients at 1 year following switch(46% vs 42%; M=F). Conclusions: EA patients switched to TAF after 2 years of TDF had improved bone and renal safety; virologic control was maintained and ALT normalization increased. The results in EA patients are comparable to those seen in the overall population.
Byun, Jong-Seon,Lee, Sang-Hyun,Jeon, Seong-Ho,Kwon, Yong-Soo,Lee, Hee-Jae,Kim, Sung-Soo,Kim, Young-Myeong,Kim, Myong-Jo,Chun, Wan-Joo The Korean Society of Pharmacology 2009 The Korean Journal of Physiology & Pharmacology Vol.13 No.4
Nitric oxide (NO) has both neuroprotective and neurotoxic effects depending on its concentration and the experimental model. We tested the effects of NG-nitro-L-arginine methyl ester (L-NAME), a nonselective nitric oxide synthase (NOS) inhibitor, and aminoguanidine, a selective inducible NOS (iNOS) inhibitor, on kainic acid (KA)-induced seizures and hippocampal CA3 neuronal death. L-NAME (50 mg/kg, i.p.) and/or aminoguanidine (200 mg/kg, i.p.) were administered 1 h prior to the intracerebroventricular (i.c.v.) injection of KA. Pretreatment with L-NAME significantly increased KA-induced CA3 neuronal death, iNOS expression, and activation of microglia. However, pretreatment with aminoguanidine significantly suppressed both the KA-induced and L-NAME-aggravated hippocampal CA3 neuronal death with concomitant decreases in iNOS expression and microglial activation. The protective effect of aminoguanidine was maintained for up to 2 weeks. Furthermore, iNOS knockout mice ($iNOS^{-1-}$) were resistant to KA-induced neuronal death. The present study demonstrates that aminoguanidine attenuates KA-induced neuronal death, whereas L-NAME aggravates neuronal death, in the CA3 region of the hippocampus, suggesting that NOS isoforms play different roles in KA-induced excitotoxicity.